Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer

Abstract

Objective To compare the clinical efficacy and safety between mXELIRI and mFOLFIRI combined with cetuximab in the first-line treatment of metastatic left-side colorectal cancer. Methods We retrospectively analyzed the clinical data of 68 patients with metastatic left-side colorectal cancer treated with cetuximab combined with mXELIRI or mFOLFIRI. We compared the objective response rate (ORR), disease control rate (DCR) and progression-free survival time (PFS) between two regimens, and evaluated the safety. Results The ORR of mXELIRI and mFOLFIRI groups were 62.5% and 58.4%, the DCR were 87.5% and 88.9%, and the median PFS were 10.5 and 9.9 months, respectively (all P > 0.05). The incidence of hand-foot syndrome (HFS) of mXELIRI group was significantly higher than that of mFOLFIRI group (37.5% vs. 13.9%, P=0.025). Conclusion Cetuximab combined with mXELIRI and mFOLFIRI in the first-line treatment of metastatic left-side colorectal cancer have equivalent efficacy and safety.

Keywords

• cetuximab
• bevacizumab
• irinotecan
• xeloda
• colorectal cancer